{"id":{"repo_id":"mit","oai_identifier":"oai:dspace.mit.edu:1721.1/57763"},"canonical_url":"https://search.dev.ndltd.org/etd/mit/oai:dspace.mit.edu:1721.1/57763","repository":{"repo_id":"mit","name":"MIT","base_url":"https://dspace.mit.edu/oai/request"},"display":{"title":"Commercialization strategies of biotechnology companies","abstract":"In the biotechnology industry today, there are many business models for project commercialization. These models range from independent vertical integration to certain forms of collaboration with pharmaceutical companies to complete acquisitions of projects by the big pharmaceutical companies. In this thesis, we wanted to study commercialization strategies of several biotechnology companies. We wanted to investigate the rational for commercialization decisions and the consequence of these decisions on biotechnology firms'. Thus, we conducted interviews with either founders or senior managers of business development of nine biotechnology firms to address these issues. Our results demonstrate that biotechnology firms reluctantly enter partnership agreements with pharmaceutical companies. In addition, there are delays in the negotiation process before agreements are reached, which can have negative impact on biotechnology firms. Furthermore, concentration on core competencies and the presence of champions at the pharmaceutical partners are two essential elements of successful commercialization for biotechnology firms.","abstract_html":"In the biotechnology industry today, there are many business models for project commercialization. These models range from independent vertical integration to certain forms of collaboration with pharmaceutical companies to complete acquisitions of projects by the big pharmaceutical companies. In this thesis, we wanted to study commercialization strategies of several biotechnology companies. We wanted to investigate the rational for commercialization decisions and the consequence of these decisions on biotechnology firms'. Thus, we conducted interviews with either founders or senior managers of business development of nine biotechnology firms to address these issues. Our results demonstrate that biotechnology firms reluctantly enter partnership agreements with pharmaceutical companies. In addition, there are delays in the negotiation process before agreements are reached, which can have negative impact on biotechnology firms. Furthermore, concentration on core competencies and the presence of champions at the pharmaceutical partners are two essential elements of successful commercialization for biotechnology firms.","abstract_has_math":false,"creators":["Saghir, Mouris"],"institution":"Massachusetts Institute of Technology","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Sloan School of Management.","school":null,"contributors":[],"advisors":["Scott Stern."],"committee_chairs":[],"committee_members":[],"year":1999,"date_issued":"1999","date_published":"1999","updated_at":"2026-07-22T22:21:38Z","subjects":["Sloan School of Management."],"languages":["eng"],"rights":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."],"rights_urls":["http://dspace.mit.edu/handle/1721.1/7582"],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/1721.1/57763","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Scott Stern."]},{"key":"dc:contributor.department","label":"Department","values":["Sloan School of Management."]},{"key":"dc:contributor.other","label":"Dc Contributor Other","values":["Sloan School of Management."]},{"key":"dc:creator","label":"Author","values":["Saghir, Mouris"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2010-08-31T14:28:03Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2010-08-31T14:28:03Z"]},{"key":"dc:date.issued","label":"Date","values":["1999"]},{"key":"dc:publisher","label":"Institution","values":["Massachusetts Institute of Technology"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Sloan School of Management."]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://dspace.mit.edu/handle/1721.1/7582"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/1721.1/57763"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 1999.","Includes bibliographical references (leaves 49-50)."]},{"key":"dc:description.abstract","label":"Abstract","values":["In the biotechnology industry today, there are many business models for project commercialization. These models range from independent vertical integration to certain forms of collaboration with pharmaceutical companies to complete acquisitions of projects by the big pharmaceutical companies. In this thesis, we wanted to study commercialization strategies of several biotechnology companies. We wanted to investigate the rational for commercialization decisions and the consequence of these decisions on biotechnology firms'. Thus, we conducted interviews with either founders or senior managers of business development of nine biotechnology firms to address these issues. Our results demonstrate that biotechnology firms reluctantly enter partnership agreements with pharmaceutical companies. In addition, there are delays in the negotiation process before agreements are reached, which can have negative impact on biotechnology firms. Furthermore, concentration on core competencies and the presence of champions at the pharmaceutical partners are two essential elements of successful commercialization for biotechnology firms."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["S.M."]},{"key":"dc:title","label":"Title","values":["Commercialization strategies of biotechnology companies"]}]}],"canonical_facts":{"dc:contributor.advisor":["Scott Stern."],"dc:contributor.department":["Sloan School of Management."],"dc:contributor.other":["Sloan School of Management."],"dc:creator":["Saghir, Mouris"],"dc:date.accessioned":["2010-08-31T14:28:03Z"],"dc:date.available":["2010-08-31T14:28:03Z"],"dc:date.issued":["1999"],"dc:description":["Thesis (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 1999.","Includes bibliographical references (leaves 49-50)."],"dc:description.abstract":["In the biotechnology industry today, there are many business models for project commercialization. These models range from independent vertical integration to certain forms of collaboration with pharmaceutical companies to complete acquisitions of projects by the big pharmaceutical companies. In this thesis, we wanted to study commercialization strategies of several biotechnology companies. We wanted to investigate the rational for commercialization decisions and the consequence of these decisions on biotechnology firms'. Thus, we conducted interviews with either founders or senior managers of business development of nine biotechnology firms to address these issues. Our results demonstrate that biotechnology firms reluctantly enter partnership agreements with pharmaceutical companies. In addition, there are delays in the negotiation process before agreements are reached, which can have negative impact on biotechnology firms. Furthermore, concentration on core competencies and the presence of champions at the pharmaceutical partners are two essential elements of successful commercialization for biotechnology firms."],"dc:description.degree":["S.M."],"dc:identifier.uri":["http://hdl.handle.net/1721.1/57763"],"dc:language.iso":["eng"],"dc:publisher":["Massachusetts Institute of Technology"],"dc:rights":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."],"dc:rights.uri":["http://dspace.mit.edu/handle/1721.1/7582"],"dc:subject":["Sloan School of Management."],"dc:title":["Commercialization strategies of biotechnology companies"],"dc:type":["Thesis"]},"updated_at":"2026-07-22T22:21:38Z"}